ArticleScientific reports2025
Trends and projections of the global and regional burden of multiple myeloma in adults aged 40 and over, 1990-2044.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next-generation sequencing-based high-risk genomic stratification in multiple myeloma.Translational cancer research · 2026Article
- Global, regional, and national metabolic risk factors associated with multiple myeloma, 1990-2021: analysis via the global burden of disease study 2021.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The objective is to examine the data from the global burden of disease (GBD) 2021 to report on the global, regional, and national trends and rates related to the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for multiple myeloma in adults aged 40 and above. Data from the GBD 2021 was used in this study to evaluate the rates of incidence, prevalence, mortality, and DALYs related to multiple myeloma across global, regional, and national scales. To analyze these trends, joinpoint regression was applied to calculate the average annual percentage changes (AAPC). Further, the analysis was divided according to age, gender, region, and socio-demographic index (SDI). Projections extending to 2044 were also generated using the Nordpred model. From 1990 to 2021, an upward trend has been observed globally in the incidence, prevalence, mortality, and DALYs of multiple myeloma among adults aged 40 and older, with average annual percentage changes (AAPCs) of 0.53 (95% CI 0.41-0.64), 1.2 (95% CI 1.07-1.33), 0.19 (95% CI 0.07-0.31), and 0.15 (95% CI 0.04-0.26), respectively. Notably, middle SDI countries exhibited the most accelerated disease progression, demonstrating a 2.34 (95% CI 2.19-2.48) annual increase in age-standardized incidence rate (ASIR)-over fourfold higher than the global average. The increasing global burden of multiple myeloma in adults aged 40 and older, especially in areas and nations with lower SDI levels, underscores the pressing requirement for customized public health initiatives and policies to tackle this escalating issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.